Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

Main Inclusion Criteria:

• Have a clinical diagnosis of suspected bacterial conjunctivitis in at least 1 eye,confirmed by the presence of purulent or mucopurulent ocular discharge and a grade ≥ 1 on the modified Validated Bulbar Redness (VBR) conjunctival redness scale.

• Have not received any ocular treatment for conjunctivitis, aside from eyelidhygiene, ≤14 days prior to Visit 1.

• Have a negative viral conjunctivitis test in both eyes.

• Agree to discontinue use of eye/eyelid cosmetics during study participation.

• Agree to discontinue use of contact lenses during study participation.

• Be willing and able to provide informed consent and comply with the studyrequirements.

• Not be currently pregnant or breastfeeding. If sexually active, agree to useapproved contraception for the duration of the study.

Main Exclusion Criteria:

• Have signs and/or symptoms or a diagnosis of fungal, protozoal, or viral etiology ≤30 days prior to Visit 1.

• Have experienced signs and symptoms of bacterial conjunctivitis for >48 hours priorto Visit 1.

• Require or are expected to require use of any non-study topical ocular medication orsystemic medications prior to Visit 1 as specified in the protocol as ineligible.

• Have any abnormality of the ocular anatomy or ocular disease/disorder specified inthe protocol as ineligible.

• Have a known intolerance, sensitivity or allergy to the study medications or any oftheir components.

• Have participated in another clinical trial ≤30 days or received anotherexperimental drug ≤90 days prior to Visit 1.

• Have a family member or household member enrolled in this study.

• Have a condition which in the investigator's opinion may impact their safety orwould negatively affect the conduct or outcome of the study.

• Be an employee of or immediate family member of an employee (directly related tostudy conduct) at the study site.